Taiwan has become the latest APAC region to approve the use of 2’-fucosyllactose (2’-FL) – a human milk oligosaccharide (HMO) – in nutrition products for infant and young children, with firms hopeful of further sector growth as more authorities permit the use of the ingredient.
You May Also Like

Bifidobacterium probiotic may incur “remarkable” benefits to infant gut, study finds
INCMarch 27, 2023

Study: Fucosylated HMOs may improve infant cognitive development, whilst sialyated types may not
INCMarch 27, 2023

Global conference on infant nutrition in Wellington
INCOctober 17, 2022